Pfizer’s local manufacturing setup is already well positioned in the U.S., and the New York-based drugmaker could bring additional resources into the country if pharma import tariffs proposed by President Donald Trump take effect, the company’s CEO, Albert Bourla, Ph.D.,
read moreOver nearly the last three decades, Genentech has had the lone medicine on the market for stroke. On Monday, the Roche subsidiary added a second stroke treatment to its repertoire, gaining an FDA endorsement for TNKase. More: Roche gains label
read moreAstraZeneca and Daiichi Sankyo’s Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partners said on Monday. More: AstraZeneca, Daiichi unblind Enhertu study early as
read moreAlready billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic rhinosinusitis with nasal polyps (CRSwNP). In reviewing the data drop, William Blair analysts said the results “hint at best-in-disease therapy.” More: Sinusitis
read moreTakeda made it rain zebras at a Boston Celtics game Friday. The stunt saw 100 toy zebras parachute from the arena’s rafters to represent the complex journeys of individuals with rare diseases. More: Takeda rains 100 toy zebras down on
read more
New research highlights NHS approval gap compared to other cancers More: Blood cancer patients face treatment access disparity Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals